Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease

E-ISSN： 1873-4286|23|6|937-943

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.6, 2017-03, pp. : 937-943

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target

Current Medicinal Chemistry, Vol. 13, Iss. 17, 2006-07 ,pp. : 1971-1978

Bentham Science Publishers

Access to resources Recommend Favorite

Kinetics, Role and Therapeutic Implications of Endogenous Soluble form of Receptor for Advanced Glycation end Products (sRAGE) in Diabetes

Current Drug Targets, Vol. 8, Iss. 10, 2007-10 ,pp. : 1138-1143

Bentham Science Publishers

Access to resources Recommend Favorite

Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication

Current Pharmaceutical Design, Vol. 14, Iss. 5, 2008-02 ,pp. : 487-495

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [ Advanced Glycation End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi ]

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 939-939

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances

Current Clinical Pharmacology, Vol. 11, Iss. 2, 2016-08 ,pp. : 118-127

Bentham Science Publishers

Access to resources Recommend Favorite